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NP_780627.2 NP_666301.2 AAI54409.1 
 
 
Identity Positives Gaps Identity Positives Gaps 
ssC1C2 53% 70% 5% 52% 67% 6% 
fsC1C2    48% 59% 8% 
MyBP-C Full 
Length ssMyBP-C fsMyBP-C cMyBP-C 
 
 
Identity Positives Gaps Identity Positives Gaps 
ssMyBP-C 51% 70% 2% 49% 67% 5% 











































Figure	 7.	 Expression	 profile	 of	 skeletal	 MyBP-C	 in	 FVB/N	 WT	 mice.	 Four	skeletal	muscles	were	 chosen	 to	 represent	 different	 types	 of	muscles.	Extensor	

















































































































Figure	 17.	 fsC1C2	 and	 C0C2	 increase	 cross-bridge	 cycling	 kinetics	 at	






 Control +ssC1C2 +fsC1C2 +C0C2 
pCa50 5.2 ± 0.46 5.47 ± 0.06 5.71 ± 0.06* 5.6 ± .16* 
Tension 
Cost 4.94 ± 0.45 3.95 ± 0.30* 2.7 ± .40** 4. 1 ± 0.36* 
ktr (pCa 6) 1.97 ± 0.98 3.70 ± 1.81 4.23 ± 0.50* 6.22 ± 0.53***# 
Force  











Baseline	 activation	 data	 for	 fibers	 were	 first	 gathered	 in	 the	 absence	 of	recombinant	 proteins,	 followed	 by	 incubation	 with	 recombinant	 proteins	 and	 a	subsequent	maximal	activation.	The	differences	between	the	second	activation	and	initial	activation	were	calculated	as	ΔForce,	ΔStiffness,	and	ΔATPase	activity	(Figure	
19).	 Results	 demonstrate	 no	 significant	 changes	 in	 these	 functional	 parameters,	regardless	of	whether	10	µM	recombinant	proteins	were	dialyzed	in	PBS	and	diH2O.	This	suggests	that	the	functional	studies	conducted	with	recombinant	proteins	at	10	µM	were	not	influenced	significantly	by	increases	in	ionic	strength.	Furthermore,	the	observed	changes	in	function	in	previous	results	(e.g.	increase	in	force)	are	opposite	of	 what	 one	would	 predict	 if	 ionic	 strength	were	 increased,	 as	 increases	 in	 ionic	strength	have	been	previously	demonstrated	to	depress	force.		
To	determine	whether	even	higher	 concentrations	of	 recombinant	proteins	dialyzed	 in	 PBS	 can	 be	 used,	 fibers	 were	 also	 tested	 in	 the	 presence	 of	 30	 µM	recombinant	 proteins.	 Results	 demonstrate	 that	 even	when	 recombinant	 proteins	were	lyophilized	and	reconstituted	to	a	final	concentration	of	30	µM,	the	contribution	of	 the	 residual	 salts	 to	 ionic	 strength	were	 not	 sufficient	 to	 significantly	 alter	 the	steady-state	functional	parameters,	with	the	exception	of	fsC1C2	dialyzed	in	PBS,	
63	
	













































































MyBP-C isoform n Kd (µM) Bmax (mol/mol actin) 
ssC1C2  7 2.08 ± 0.76* 0.45 ± 0.15*# 
fsC1C2 6 10.51 ± 4.75 1.14 ± 0.25 






















Figure	 23.	 3D	 reconstructions	 of	 reconstituted	 thin	 filament	 and	 MyBP-C	






























Isoform φ1 φ2 r1 r2 r∞ 
None 182±10 26±2 0.042±0.002 0.036±0.002 0.035±0.005 
C0C2 221±18 19±3 0.014±0.002* 0.030±0.003 0.079±0.006* 
fsC1C2 326±19* 21±3 0.023±0.002* 0.021±0.002* 0.062±0.008* 






































































































isoform kb ku kon koff fapp gapp hf hb gxb gammaB 
Temp. 
(K) 
ssMyBP-C 0.09 0.45 375 0.33 0.30 70e-3 2000e-3 400e-3 0.25 300 323 
fsMyBP-C 0.09 0.45 360 0.33 0.30 70e-3 2000e-3 400e-3 0.25 300 323 
cMyBP-C 0.09 0.45 500 0.33 0.30 70e-3 2000e-3 400e-3 0.25 300 323 







































Figure	30.	Targeting	 strategy	 for	 FSKO	mice.	 (top)	wild-type	 fsMyBP-C	 gene	(bottom)	 targeted	 fsMyBP-C	 gene.	 Exons	 2-22	 were	 replaced	 with	 a	 neomycin	resistance	gene.		
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 Report for ES Microinjection and Germline F1 Breeding Products 
 
Customer Sakthivel Sadayappan 
Institution Loyola University Chicago 
Contract No. TGS130228I10 
Germline F1 Information 
Name of ES Clone LUC002_ mMybpc2_1B9 
Breeding Mouse Strain(♀) C57BL/6 Coat Color Black 
No. of Pups 10 Coat Color Black 
Date of Birth (F1) 04-26-2014. 
Description Total: 10 pups; LUC002_1B9 1 to 10. 
PCR-Positive Pups 
♂ 3 LUC002_1B9：1, 5, 9. 
♀ 1 LUC002_1B9：3. 
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